BGF Global Equity Income E2 (EUR) |
Performance History | 30/09/2024 |
Growth of 1,000 (EUR) |
Fund | -4.0 | 25.7 | -10.1 | 10.8 | 11.0 | |
+/-Cat | -0.5 | -0.4 | -4.0 | 1.0 | -2.2 | |
+/-Idx | - | -2.7 | -11.2 | 3.5 | -3.1 | |
Category: Global Equity Income | ||||||
Benchmarks: Morningstar Gbl High Div Yl... |
Key Stats | ||
NAV 04/10/2024 | EUR 21.44 | |
Day Change | 0.80% | |
Morningstar Category™ | Global Equity Income | |
ISIN | LU0628613043 | |
Fund Size (Mil) 30/08/2024 | USD 976.91 | |
Share Class Size (Mil) 04/10/2024 | USD 24.29 | |
Max Initial Charge | 3.00% | |
Ongoing Charge 15/04/2024 | 2.31% |
Investment Objective: BGF Global Equity Income E2 (EUR) |
The Fund seeks an above average income from its equity investments without sacrificing long term capital growth. The Fund invests globally at least 70% of its total assets in the equity securities of companies domiciled in, or exercising the predominant part of their economic activity in, developed markets. Currency exposure is flexibly managed. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Olivia Treharne 01/02/2020 | ||
Molly Greenen 12/01/2022 | ||
Inception Date 20/05/2011 |
Advertisement |
Benchmarks | |
Fund Benchmark | Morningstar Benchmark |
MSCI ACWI NR USD | Morningstar Gbl High Div Yld NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for BGF Global Equity Income E2 (EUR) | 31/08/2024 |
|
|
Top 5 Holdings | Sector | % |
Microsoft Corp | Technology | 4.91 |
AstraZeneca PLC | Healthcare | 3.17 |
Texas Instruments Inc | Technology | 3.17 |
Apple Inc | Technology | 3.14 |
Novo Nordisk AS Class B | Healthcare | 3.13 |
Increase Decrease New since last portfolio | ||
BGF Global Equity Income E2 (EUR) |